Morgan Stanley Maintains Equal-Weight on BioNTech, Lowers Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has maintained an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and lowered the price target from $119 to $116.
August 08, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Equal-Weight rating on BioNTech and lowered the price target from $119 to $116.
The news is directly related to BioNTech and is likely to influence investor sentiment. The lowering of the price target may suggest a slightly less optimistic outlook for the company, but the maintenance of the Equal-Weight rating indicates that the analyst still sees the stock as fairly valued.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100